Adebrelimab plus chemotherapy vs. chemotherapy for treatment of extensive-stage small-cell lung cancer from the US and Chinese healthcare sector perspectives: a cost-effectiveness analysis to inform drug pricing

Purpose: The aim of this study was to evaluate the cost-effectiveness of a recently approved first-line therapy (adebrelimab plus chemotherapy vs. chemotherapy alone) for patients with extensive-stage small-cell lung cancer (ES-SCLC) in the US and China, and to estimate the reasonable range of adebr...

Descripción completa

Detalles Bibliográficos
Autores principales: Gan, Yena, Shi, Fenghao, Zhu, He, Han, Sheng, Li, Duoduo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398383/
https://www.ncbi.nlm.nih.gov/pubmed/37547339
http://dx.doi.org/10.3389/fphar.2023.1241130

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398383/
https://www.ncbi.nlm.nih.gov/pubmed/37547339
http://dx.doi.org/10.3389/fphar.2023.1241130

Ejemplares similares